Request Demo

Last update 14 Feb 2026

Dopamine hydrochloride

Last update 14 Feb 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryDopamine hydrochloride, first approved in the USA on February 25, 1974, is a medication developed and marketed by Hospira. It is indicated for the treatment of heart failure and shock. Dopamine hydrochloride works as a dopamine agonist, which means that it binds to and activates dopamine receptors in the body. This results in increased cardiac output and improved blood flow to vital organs. The chemical name for dopamine hydrochloride is 3,4-dihydroxyphenethylamine hydrochloride. As the hydrochloride salt form of dopamine, it is more stable and soluble in water, making it suitable for intravenous administration in clinical settings.

Drug Type

Small molecule drug

Synonyms

Dopamine hydrochloride (JP17/USP), ASL-279, BCO-001

+ [8]

Target

DRDs

Action

agonists

Mechanism

DRDs agonists(Dopamine receptors agonists)

Therapeutic Areas

Cardiovascular DiseasesOther DiseasesNervous System Diseases+ [1]

Active Indication

BradycardiaHypotensionShock, Cardiogenic+ [3]

Inactive Indication

Cerebral Intraventricular HemorrhageHeart Failure

Originator Organization

Hospira, Inc.

Active Organization

Terumo Corp.BrePco Biopharma Ltd.

Piramal Pharma Ltd.

+ [5]

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (25 Feb 1974),

Heart Failure

RegulationOrphan Drug (United States)

Structure/Sequence

Molecular FormulaC8H12ClNO2

InChIKeyCTENFNNZBMHDDG-UHFFFAOYSA-N

CAS Registry62-31-7

Clinical Trials associated with Dopamine hydrochloride

NCT07322133

/ RecruitingPhase 4IIT

Dopamine vs. Norepinephrine in Term and Late Preterm Neonates With Hypoxemic Respiratory Failure and Systemic Hypotension Due to Pulmonary Hypertension: A Pilot Trial

This pilot randomized clinical trial compares dopamine and norepinephrine as first-line vasoactive therapies in term and late preterm neonates with pulmonary hypertension associated with hypoxemic respiratory failure and systemic hypotension. Systemic hypotension is a common and clinically significant complication of persistent pulmonary hypertension of the newborn (PPHN) and frequently requires vasopressor support to maintain adequate systemic perfusion. Dopamine is commonly used in this setting; however, prior animal experimental and clinical data suggest it may increase pulmonary vascular resistance, potentially worsening right ventricular afterload and hypoxemia. Norepinephrine may preferentially increase systemic vascular resistance with less effect on the pulmonary circulation. This study evaluates short-term hemodynamic and oxygenation responses following initiation of dopamine or norepinephrine.

Start Date01 Jun 2026

Sponsor / Collaborator

University of California, Davis

[+1]

NCT06611423

/ TerminatedPhase 1

A Phase Ib, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)

The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).

Start Date15 Oct 2024

Sponsor / Collaborator

AstraZeneca PLC

[+2]

CTRI/2024/09/073777

/ Not yet recruitingPhase 3IIT

Comparison of Norepinephrine, Epinephrine and Dopamine in the treatment of Neonatal septic shock: A Randomized Controlled Trial - The DENSe Trial

Start Date20 Sep 2024

Sponsor / Collaborator

Indian Council of Medical Research

100 Clinical Results associated with Dopamine hydrochloride

100 Translational Medicine associated with Dopamine hydrochloride

100 Patents (Medical) associated with Dopamine hydrochloride

90,140

Literatures (Medical) associated with Dopamine hydrochloride

01 Aug 2026·BIOELECTROCHEMISTRY

RNA aptamer-modified gold-plated carbon fiber microelectrodes for selective dopamine sensing

Article

Author: Bache, Christian Meinert ; Shipovskov, Stepan ; Ewing, Andrew ; Ferapontova, Elena E ; López Mujica, Michael E J

Specific electroanalysis of neurotransmitters in the brain, bloodstream, cerebrospinal fluid (CSF), or at the cellular level critically depends on the availability of miniaturized electrodes for aptasensing. Yet, with electrode miniaturization, sensitivity of analysis and limits of detection (LOD) can be compromised. Here, we adapted the RNA-aptamer-based macroelectrode assay for dopamine to the microelectrode format, by using gold-plated carbon fiber microelectrodes (CFE), modified via thiol chemistry with cysteamine and an RNA aptamer, for specific dopamine detection. The sensitivity of analysis with gold-plated cylindrical microelectrodes improved 90-fold, to 9.75 μA μM^-1 cm^-2 (at +0.100 V) vs. 108 nA μM^-1 cm^-2 (at optimal +0.185 V) shown with gold disk macroelectrodes, with LOD being 60 and 100 nM, in PBS and in artificial CSF, respectively. Yet, epinephrine interfered at 0.1 V. At 0.05 V, the sensitivity dropped to 4.62 μA μM^-1 cm^-2 but the RNA-aptamer/cysteamine-modified CFEs demonstrated excellent selectivity for dopamine over epinephrine, norepinephrine, L-DOPA, DOPAC, and uric and ascorbic acids. These findings suggest a straightforward strategy for constructing biospecific aptamer-based microelectrodes. However, in matrices more complex than CSF, such as serum, dopamine oxidation was inhibited. Therefore, effective monitoring of dopamine levels in blood using aptamer microelectrodes will likely require the use of protective membranes.

01 May 2026·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Evaluating the interactions of L-DOPA and droxidopa toward D 3 dopamine receptor through computational study: A comparison with dopamine

Article

Author: Baro, Bhabesh ; Sarkar, Biplab

The D₃ dopamine receptor (D₃R), a member of the G protein-coupled receptor family, plays a critical role in neurophysiological processes and has emerged as a potential target for treating neurological disorders such as Parkinson's disease. In this study, we employed computational approaches to investigate the molecular interactions of D₃R with dopamine and two key dopamine precursors: L-DOPA and droxidopa. Molecular docking was conducted to evaluate binding affinities and identify key receptor-ligand interactions, followed by molecular dynamics simulations to assess the stability and dynamic behavior of the complexes in a biological environment. MM-PBSA binding free energy calculations were used to further quantify the strength of ligand binding to D₃R.

01 May 2026·BIOMATERIALS

Hydrogel-guided p-LOX nanodrug delivery modulates metabolic microenvironment for cartilage repair in osteoarthritis

Article

Author: Zhao, Rui ; Wang, Sixiang ; Feng, Fan ; Sha, Yongqiang ; Weng, Xisheng ; Xu, Kang ; Wu, Min ; Chi, Qingjia ; Xu, Chunming ; Shen, Jianliang ; Huang, Linwei ; Wu, Jiaqin ; Qian, Yuna ; Wang, Chunli

Osteoarthritis (OA) is a common degenerative disorder characterized by joint inflammation and progressive loss of cartilage. Anti-OA therapies are still lacking. The hallmark of OA pathoetiology is an imbalance in metabolic activities that causes persistent inflammation and an intrinsic loss of regenerative capacity. In the present study, we discovered that lysyl oxidases (LOXs) were downregulated in clinical samples of patients with OA. LOX supplementation remodeled the metabolic microenvironment via an anti-inflammatory effect. We constructed a positively charged LOX-based (p-LOX) nanodrug delivery system guided by a hydrogel (HG), which consisted of photo-crosslinked hyaluronic acid and dopamine. The HG-p-LOX system delivered sustained release of the p-LOX nanodrug for up to 20 days following a one-time intra-articular administration, which effectively repaired cartilage defects and inhibited the pathoetiology of OA. Mechanistically, we discovered that HG-p-LOX delivery altered the OA microenvironment by targeting glycolysis-mediated lactate production in chondrocytes. p-LOX was observed to exert a hitherto unrecognized role in modulating histone lactylation, which is essential for the transcription of target genes linked to inflammatory conditions. We also used SRY-Box Transcription Factor 9-Cre recombinase mutated estrogen receptor 2/lactate dehydrogenase A^{floxed/floxed} transgenic mice to validate the critical role of lactate in LOX-mediated inflammation. Thus, the HG-p-LOX nanodrug delivery system may represent a novel drug target and a potential clinical treatment for OA repair.

News (Medical) associated with Dopamine hydrochloride

09 Feb 2026

·www.biospace.com

PreveCeutical Announces Filing of Patent for Delivery of CNS-Active Agents

Vancouver, British Columbia--(News - February 9, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical") is pleased to announce it has filed an International (PCT) patent application on February 5, 2026, having the application no. PCT/US2026/014110, and entitled "Delivery of CNS-active therapeutic agents". The international patent application covers innovative methods and formulations aimed at addressing longstanding challenges in the treatment of neurological diseases and disorders. Of particular interest is Parkinson's disease, which is a neurodegenerative condition afflicting over 10 to 12 million globally, and it is cited as the 2 nd most common neurodegenerative disorder after dementia. Progressive symptoms of Parkinson's disease include unilateral movement issues, typically presenting as a slight tremor and quiet speech in the early stages, through to severe disability that impacts eating, bathing and dressing, complemented by cognitive decline. Depletion of the neurotransmitter dopamine in the brain is the key driver of Parkinson's. Direct supplementation with dopamine is not currently a viable option, due to it being unable to cross the blood-brain barrier, and treatments most typically involve oral administration of the dopamine precursor, levodopa (L-dopa). As Parkinson's is a progressive disease also impacting the health of dopaminergic neurons, their gradual decline in numbers is inevitable, reaching a threshold that renders supplementation with L-dopa ineffective. PreveCeutical has now developed an approach for the delivery of central nervous system (CNS)-active drugs, such as dopamine, directly to the brain, and formulations that are adapted for this delivery mode. By supplying the native neurotransmitter (dopamine) directly to the brain, the Company proposes circumventing the need to administer L-dopa, dopamine agonists and other therapeutics progressively prescribed for the management of Parkinson's across the spectrum of disease. Furthermore, this approach has the potential to offer patients in the advanced stages of Parkinson's a safe and effective treatment option, through direct replenishment of dopamine in the brain, potentially circumventing the need for advanced/invasive treatments. More broadly, PreveCeutical's novel approach has the potential to address historical bottlenecks in the delivery of a range of peripherally-restricted therapeutics for CNS conditions, and it is actively exploring options to exploit these opportunities. Commenting on the filing, PreveCeutical Chief Executive Officer Stephen Van Deventer stated, " Despite decades of research, there is still no proven clinical strategy for delivering dopamine directly to the brain. Our technology aims to change that, and we believe it represents an important step toward transforming the treatment landscape for Parkinson's disease and other central nervous system disorders. " The Company is not making any express or implied claims that its product and approach has the ability to manage Parkinson's disease at this time. Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful. About PreveCeutical PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). For more information about PreveCeutical, please visit our website or follow us on Twitter and Facebook . On behalf of the Board of Directors of PreveCeutical Stephen Van Deventer, Chairman and Chief Executive Officer For further information, please contact: Stephen Van Deventer: +1 604 306 9669 Or Investor Relations ir@preveceutical.com Neither the CSE nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Statements: Certain information in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements in this news release include: that the Company's patent will be successfully granted by the regulators; that the Company's technology for delivering drugs directly to the brain by directly crossing the blood-brain barrier will be successful and that the Company's technology will be a treatment for Parkinson's disease or have any positive effects on those with Parkison's disease. Forward-looking information is based on reasonable assumptions that have been made by PreveCeutical as at the date of such information and is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of PreveCeutical to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the risk of PreveCeutical not obtaining the patent applied for; the risk that the technology which is the subject of the patent not successfully working for the administration of drugs directly through the blood-brain barrier; the risk that the Company will not have access to the necessary capital to operate its business; the accuracy of PreveCeutical's projections and estimates; interest and exchange rates; competition; share price fluctuations; actual results of activities; government regulation; political or economic developments; environmental risks; insurance risks; capital expenditures; operating or technical difficulties in connection with research and development activities; personnel relations; changes and volatility in project parameters as plans continue to be refined; the inherent uncertainties regarding cost estimates, financing, cost overruns, availability of materials and equipment, timeliness of government approvals, taxation, political risk and related economic risk; global financial conditions; the market price of PreveCeutical's securities; ability to access capital; changes in interest rates; liabilities and risks inherent in research and development operations; the potential influence of or reliance upon PreveCeutical's business partners, and the adequacy of insurance coverage. Forward-looking information is based on certain assumptions that PreveCeutical believes is reasonable, including that the technology which is the subject of the patent is successful in the administration of drugs directly through the blood-brain barrier; sufficient working capital will be available for operation of the business; that the general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed on reasonable terms and that PreveCeutical will not experience any material labour dispute, accident, or failure of plant or equipment, as well as the risks and uncertainties which are more fully described in the Company's annual and quarterly management's discussion and analysis and in other filings made by the Company with Canadian securities regulatory authorities under the Company's SEDAR+ profile. Although PreveCeutical has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers should not place undue reliance on forward-looking information. PreveCeutical does not undertake to update any forward-looking information contained herein or that is incorporated by reference herein, except in accordance with applicable securities laws. To view the source version of this press release, please visit

27 Jan 2026

·www.businesswire.com

Otsuka Announces FDA Acceptance and Priority Review of New Drug Application for Centanafadine for the Treatment of ADHD in Children, Adolescents, and Adults

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announce that the U.S. Food and Drug Administration (FDA) has accepted for priority review the New Drug Application (NDA) for centanafadine, an investigational, once-daily extended release capsule and the first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. The Prescription Drug User Fee Act (PDUFA) target action date is set for July 24, 2026. The NDA is supported by results from four pivotal Phase 3 clinical trials evaluating the efficacy and safety of centanafadine across patient populations1,2,3. In these trials, centanafadine demonstrated statistically significant and clinically meaningful improvements in ADHD symptoms compared with placebo, as measured by the ADHD Rating Scale – 5 (ADHD-RS-5) in adolescents and children, and the ADHD Investigator Symptom Rating Scale (AISRS) in adults. Centanafadine was generally well tolerated across studies, with the most common adverse events including decreased appetite, nausea, rash, fatigue, abdominal pain, and somnolence in children and adolescents, and decreased appetite and headache in adults1,2,3. “ADHD manifests differently across patients, highlighting the importance of having multiple therapeutic approaches available,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka Pharmaceutical Development & Commercialization, Inc. “The FDA’s acceptance and priority review designation of our NDA for centanafadine marks an important milestone in our effort to bring forward a novel treatment option for people living with ADHD. If approved, centanafadine would offer a first-in-class NDSRI option designed to support broad symptom management. We extend our sincere gratitude to the patients, caregivers, and investigators whose participation made this milestone possible.” Although historically seen as a childhood disorder, research suggests that many individuals diagnosed with ADHD in childhood continue to experience symptoms into adulthood, with some patients experiencing significant impairment. About Attention-Deficit Hyperactivity Disorder (ADHD) ADHD is a chronic neurodevelopmental disorder characterized primarily by impairments in attention, hyperactivity, and impulsivity4. It affects approximately 7 million children in the U.S. and an estimated 15.5 million adults, according to the Centers for Disease Control and Prevention (CDC)5,6. About Centanafadine Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). Clinical studies have shown that centanafadine significantly reduces core symptoms of ADHD in children, adolescents, and adults. Clinical and preclinical data suggest centanafadine showed a favorable safety and tolerability profile and low potential for abuse. About Otsuka Otsuka Pharmaceutical Co., Ltd. is a global healthcare company with the corporate philosophy: Otsuka–people creating new products for better health worldwide. Otsuka researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health. In pharmaceuticals, Otsuka is a leader in the challenging areas of mental, kidney, and cardiovascular health and has additional research programs in oncology and on several under-addressed diseases including tuberculosis, a significant global public health issue. These commitments illustrate how Otsuka is a “big venture” company at heart, applying a youthful spirit of creativity in everything it does. Otsuka established a presence in the U.S. in 1973 and today its U.S. affiliates include Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Otsuka America Pharmaceutical, Inc. (OAPI). These two companies’ 2,250 employees in the U.S. develop and commercialize medicines in the areas of mental health and nephrology, using cutting-edge technology to address unmet healthcare needs. OPDC and OAPI are indirect subsidiaries of Otsuka Pharmaceutical Co., Ltd., which is a subsidiary of Otsuka Holdings Co., Ltd. headquartered in Tokyo, Japan. The Otsuka group of companies employed 35,340 people worldwide and had consolidated sales of approximately USD 14.7 billion in 2024. All Otsuka stories start by taking the road less traveled. Learn more about Otsuka in the U.S. at www.otsuka-us.com and connect with us on LinkedIn and Twitter at @OtsukaUS. Otsuka Pharmaceutical Co., Ltd.’s global website is accessible at https://www.otsuka.co.jp/en/. References Ward, Caroline L., et al. “Efficacy and safety of centanafadine for ADHD treatment in children: A randomized clinical trial.” Pediatrics Open Science , vol. 1, no. 3, 1 July 2025, pp. 1–11, https://doi-org.libproxy1.nus.edu.sg/10.1542/pedsos.2024-000349 . Ward, Caroline L., Ann C. Childress, et al. “Centanafadine for attention-deficit/hyperactivity disorder in adolescents: A randomized clinical trial.” Journal of the American Academy of Child & Adolescent Psychiatry , July 2025, https://doi-org.libproxy1.nus.edu.sg/10.1016/j.jaac.2025.06.023 . Adler, Lenard A., et al. “Efficacy, safety, and tolerability of Centanafadine sustained-release tablets in adults with attention-deficit/hyperactivity disorder.” Journal of Clinical Psychopharmacology , vol. 42, no. 5, 2 June 2022, pp. 429–439, https://doi-org.libproxy1.nus.edu.sg/10.1097/jcp.0000000000001575 . American Psychiatric Association (2022). Diagnostic and Statistical Manual of Mental Disorders (5 th ed., text rev). “Data and Statistics on ADHD.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/adhd/data/index.html . “Facts about ADHD in Adults.” Centers for Disease Control and Prevention, Centers for Disease Control and Prevention, www.cdc.gov/adhd/php/adults/ . JANUARY 2026 26US25EBC0003

Phase 3NDAClinical ResultPriority Review

15 Jan 2026

·www.einpresswire.com

Mark Cuban Cost Plus Drugs and Alchem Laboratories Announce Alliance to Advance Essential Medicines

DALLAS, TX, UNITED STATES, January 15, 2026 / EINPresswire.com / -- Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) and Alchem Laboratories Corporation (Alchem) today announced the formation of a strategic alliance to develop essential medicine therapeutics, improving supply chain resiliency. Cost Plus Drugs is employing a highly automated and flexible manufacturing platform that integrates AI and machine learning for real-time quality assessment and process optimization to produce lidocaine, a widely used anesthetic, and diltiazem, a calcium channel blocker used to treat heart conditions., Alchem provided process development of these APIs for Cost Plus Drugs. Alchem has experience performing process development, scale-up, and GMP manufacturing of over 200 APIs, including the USP APIs amikacin, atropine, carboplatin, ciprofloxacin, cisplatin, dantrolene, dobutamine, dopamine, fluconazole, levofloxacin, linezolid, metronidazole, phentolamine, sulfamethoxazole, trimethoprim, and verteporfin. Under the terms of the agreement, the parties will also collaborate to supply 86 essential medicines and medical countermeasures including critical care drugs and antimicrobials. In September 2025, Alchem Laboratories and Applied Pharmaceutical Innovation (API-Canada) announced a Strategic Alliance to advance Antimicrobial and Essential Medicines Programs. This new alliance expands work under that collaboration, providing enhanced and equitable access to antimicrobial agents and essential medicines, with North American onshoring of critical therapies to support public needs. Alchem and API-Canada will initially work on lidocaine and diltiazem vial supply for Canada, as well as antimicrobials and vial manufacturing. As part of the arrangement, API-Canada will also support diltiazem and lidocaine vial supply more broadly as required by the collaborators. Both Alchem and Cost Plus Drugs maintain the flexibility to pursue funding and development pathways commensurate with project maturity and strategic alignment. About Mark Cuban Cost Plus Drugs The Mark Cuban Cost Plus Drug Company, PBC (Cost Plus Drugs) aims to fundamentally change the way the pharmaceutical industry operates. As a public-benefit corporation, its social mission of improving public health is just as important as the bottom line. Cost Plus Drugs transparently charges a standard markup on every drug it sells. The costplusdrugs.com online pharmacy launched in January 2022 now carries over 2,300 prescription products, delivered by mail to thousands of happy customers every day. Customers can also go to participating retail pharmacies to receive Cost Plus Drugs pricing through the Team Cuban Card. Cost Plus Drugs is working with health plans, managed-care organizations, PBMs, and self-insured employers to bring these same savings to benefit plans nationwide. Learn more at www.markcubancostplusdrugcompany.com . Dr. Alex Oshmyansky, CEO Mark Cuban Cost Plus Drugs press@costplusdrugs.com About Alchem Laboratories Corporation Alchem Laboratories Corporation is a pharmaceutical development company dedicated to advancing therapies in areas of high unmet medical need, with an emphasis on accessible, high-quality essential medicines. Alchem is a subsidiary of TRON Group Inc. (OTC:TGRP). Dr. James D Talton, CEO Alchem Laboratories Corporation info@alchem.com About Applied Pharmaceutical Innovation Applied Pharmaceutical Innovation is one of Canada’s largest not-for-profit life sciences commercialization organizations. Headquartered in Edmonton, Alberta, Applied Pharmaceutical Innovation works to accelerate the development, manufacturing, and commercialization of life sciences products, and is home to Canada’s largest security of supply initiative. Jenna Bienert Applied Pharmaceutical Innovation communications@appliedpharma.ca Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

License out/in

100 Deals associated with Dopamine hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00633	-	C01CA04	DBSALT000508

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bradycardia	United Kingdom	Piramal Pharma Ltd.	21 Mar 2025
Hypotension	European Union	BrePco Biopharma Ltd.	27 May 2024
Hypotension	Iceland	BrePco Biopharma Ltd.	27 May 2024
Hypotension	Liechtenstein	BrePco Biopharma Ltd.	27 May 2024
Hypotension	Norway	BrePco Biopharma Ltd.	27 May 2024
Shock, Cardiogenic	Japan	Tsuruhara Pharmaceutical Co. Ltd.	01 Oct 1987
Shock, Hemorrhagic	Japan	Tsuruhara Pharmaceutical Co. Ltd.	01 Oct 1987
Shock	United States	Hospira, Inc.	19 May 1981
Heart Failure	United States	Hospira, Inc.	25 Feb 1974

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cerebral Intraventricular Hemorrhage	Phase 3	Belgium	BrePco Biopharma Ltd.	01 Feb 2015
Cerebral Intraventricular Hemorrhage	Phase 3	Canada	BrePco Biopharma Ltd.	01 Feb 2015
Cerebral Intraventricular Hemorrhage	Phase 3	Czechia	BrePco Biopharma Ltd.	01 Feb 2015
Cerebral Intraventricular Hemorrhage	Phase 3	Ireland	BrePco Biopharma Ltd.	01 Feb 2015
Cerebral Intraventricular Hemorrhage	Phase 3	United Kingdom	BrePco Biopharma Ltd.	01 Feb 2015
Parkinson Disease	Phase 2	France	InBrain Pharma SAS	18 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00465452 (CTgov)	Phase 3	Parkinson Disease	11	Continuous Release Dopamine Agonists	qinakjthhg(jjbteyuusx) = qushiuxphq otmaymmxez (ebvfujakqk, aydiofplds - kesawrkswe) View more	-	16 May 2025
NCT04332276 (Pubmed) Manual	Phase 1/2	Parkinson Disease	9	Intracerebroventricular anaerobic dopamine	bmxmghfmmx(cecqizdidm) = significantly reduced on A-dopamine compared with that on oral treatment alone (P = 0.027), with a median within-patient difference of -10.4 (Hedge g = -0.62 (95% confidence interval: -1.43, -0.08)) nvfvicucvv (wsuhxznecj ) View more	Positive	07 Jan 2025
				optimized oral antiparkinsonian therapy
NCT02726620 (CTgov)	Not Applicable	Hypotension	22,435	Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Usual Care Group)	hzmictzswp = ptyxwimhkg qocribbnko (auyxlkwvkz, kjakppmzzy - mporqwdwfy) View more	-	16 May 2019
				Central neuraxial anesthesia+Dopamine+Glycopyrrolate+Hydroxyethyl starch solutions+Epinephrine+Desflurane+Sodium Chloride 0.9%+propofol+Atropine+Ephedrine+Bupivacaine+Isoflurane+Dobutamine+Vasopressin+Isoproterenol+Norepinephrine+Prilocaine+Benzocaine+Procaine+Terlipressin+Tetracaine+ropivacaine+Articaine+Levobupivacaine+Milrinone+Phenylephrine+Sevoflurane+Mepivacaine+Lidocaine+Chloroprocaine (Hypotension Decision Support)	hzmictzswp = ubgkczszdm qocribbnko (auyxlkwvkz, rqapkiqhku - vrnwelcnjd) View more
Pubmed \| Pediatr Crit Care Med	Phase 3	Shock, Septic First line	60	Dopamine	ckhlljytto(olxtbaxqaa) = nuxckskbyc znvrocnzjq (sfobecnqxj ) View more	Positive	01 Nov 2016
				Epinephrine	ckhlljytto(olxtbaxqaa) = ulczgdzvah znvrocnzjq (sfobecnqxj ) View more
NCT01132846 (ROSE/RED ROSE \| ROSE AHF \| ROSE, CTgov)	Phase 2	Dyspnea \| Heart Failure	360	Dopamine (Low Dose Dopamine)	gdfqdetvsk(idnlavwcup) = hxskollswy iffutfgfkf (wsguzyolyr, .32) View more	-	21 Aug 2014
				Placebo (Placebo)	gdfqdetvsk(idnlavwcup) = olojwzsmeg iffutfgfkf (wsguzyolyr, .27) View more
NCT01060293 (Dopamine in Acute Decompensated Heart Failure II (DAD-HF II), Pubmed \| Int J Cardiol)	Phase 4	Acute decompensated heart failure	161	High-dose furosemide	sfjlugmduw(yqaapwobeq) = rgukfcuexy qkrmejlsuq (ubrdlpmhre ) View more	-	01 Mar 2014
				Low-dose furosemide and low-dose dopamine	sfjlugmduw(yqaapwobeq) = cymiucqnmi qkrmejlsuq (ubrdlpmhre ) View more
NCT01132846 (ROSE, Pubmed \| JAMA)	Phase 2	Renal Insufficiency \| Heart Failure	360	Low-dose dopamine	ehprwmilzc(dhkssqnnch) = dsbqgteyas ddqrkjhdbs (xbiffdmqps, 0.06 - 0.18)	Negative	18 Dec 2013
				Low-dose nesiritide	ehprwmilzc(dhkssqnnch) = ensnkdbghc ddqrkjhdbs (xbiffdmqps, 0.01 - 0.13)
NCT00604019 (CTgov)	Phase 3	Shock, Septic	252	Dopamine (Dopamine)	cqjboiniie = mwwdimtwui osytmjdxiq (jymredxaaf, cejdfbdlwa - ndfbpyzkpz) View more	-	07 Dec 2012
				Norepinephrine (Norepinephrine)	cqjboiniie = emqmevpmie osytmjdxiq (jymredxaaf, wzboryjzem - qeilpckjyz) View more
NCT00115115 (Pubmed \| J Am Coll Cardiol)	Phase 4	-	93	Dopamine-treated graft	zrwzooxiiy(huvwiqymvu) = jswtivubdu isszasosof (aosqeupwym ) View more	-	18 Oct 2011
				Untreated graft	zrwzooxiiy(huvwiqymvu) = xgxkheatah isszasosof (aosqeupwym ) View more
NCT00604019 (Pubmed \| Shock)	Phase 3	Shock, Septic	252	Dopamine	uuznescvsf(fmoozwcqla) = uiqxemjcmk xxexprikoi (cpxpumgphp ) View more	-	01 Apr 2010
				Norepinephrine	uuznescvsf(fmoozwcqla) = vfoztnlqvb xxexprikoi (cpxpumgphp ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis